- 1 **Title**: Severe acute respiratory syndrome (SARS) mathematical models and disease
- 2 parameters: a systematic review and meta-analysis
- 4 **Authors**: Christian Morgenstern<sup>1,\*,#</sup>, Thomas Rawson<sup>1,\*</sup>, Isobel Routledge<sup>1</sup>, Mara Kont<sup>1</sup>,
- 5 Natsuko Imai-Eaton<sup>1</sup>, Janetta Skarp<sup>1</sup>, Patrick Doohan<sup>1</sup>, Kelly McCain<sup>1</sup>, Rob Johnson<sup>1</sup>, H.
- 6 Juliette T. Unwin<sup>4,1</sup>, Tristan Naidoo<sup>1</sup>, Dominic P Dee<sup>1</sup>, Kanchan Parchani<sup>1</sup>, Bethan N
- 7 Cracknell Daniels<sup>1</sup>, Anna Vicco<sup>1</sup>, Kieran O. Drake<sup>1</sup>, Paula Christen<sup>1</sup>, Richard J
- 8 Sheppard<sup>1</sup>, Sequoia I Leuba<sup>1</sup>, Joseph T Hicks<sup>1</sup>, Ruth McCabe<sup>1</sup>, Rebecca K Nash<sup>1</sup>, Cosmo
- 9 N Santoni<sup>1</sup>, Pathogen Epidemiology Review Group<sup>m</sup>, Gina Cuomo-Dannenburg<sup>1</sup>, Sabine
- van Elsland<sup>1</sup>, Sangeeta Bhatia<sup>1,3,^</sup>, and Anne Cori<sup>1,2,^</sup>
- 12 **Affiliations**:

11

19

23

- 13 MRC Centre for Global Infectious Disease Analysis & WHO Collaborating Centre for
- 14 Infectious Disease Modelling, Jameel Institute, School of Public Health, Imperial
- 15 College London, UK
- <sup>2</sup>Health Protection Research Unit in Modelling and Health Economics
- <sup>3</sup>Modelling and Economics Unit, UK Health Security Agency, London, UK
- <sup>4</sup>School of Mathematics, University of Bristol, Bristol, UK
- 20 \*, ^ Contributed equally
- 21 <sup>m</sup> Membership of group authorship is listed in the Supplementary Information
- 22 \*\*Corresponding author: c.morgenstern@imperial.ac.uk

**Abstract** We conducted a systematic review (PROSPERO CRD42023393345) of severe acute respiratory syndrome (SARS) transmission models and parameters characterising its transmission, evolution, natural history, severity, risk factors and seroprevalence. Information was extracted using a custom database and quality assessment tool. We extracted 519 parameters, 243 risk factors, and 112 models from 288 papers. Our analyses show SARS is characterised by high lethality (case fatality ratio 10.9%), transmissibility (R<sub>0</sub> range 1.1-4.59), and is prone to superspreading (20% top infectors causing up to 91% of infections). Infection risk was highest among healthcare workers and close contacts of infected individuals. Severe disease and death were associated with age and existing comorbidities. SARS's natural history is poorly characterised, except for the incubation period and mean onset-to-hospitalisation. Our associated R package, epireview, contains this database, which can continue to be updated to maintain a living review of SARS epidemiology and models, thus providing a key resource for informing response to future coronavirus outbreaks. **Keywords**: SARS-CoV-1, systematic review, epidemiological parameters, transmissibility, mathematical model. 

# Introduction

- The COVID-19 pandemic re-emphasised the threat posed by coronaviruses to global health.
- 62 Three coronaviruses to date, SARS-CoV-1, MERS-CoV, and SARS-CoV-2, have caused
- 63 large disruptive epidemics affecting multiple countries (1–3). SARS-CoV-2 is now endemic
- in humans, as are four other coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1),
- 65 jointly contributing to a large respiratory infection burden globally (4).
- 66 SARS-CoV-1 (or SARS-CoV) is the first documented coronavirus to have caused an acute
- 67 epidemic in humans. Cases of atypical pneumonia were reported in November 2002 (5), with
- the World Health Organization (WHO) issuing a global alert in mid-March 2003 for Severe
- 69 Acute Respiratory Syndrome (SARS). Later that month, a new airborne coronavirus, SARS-
- 70 CoV-1, was identified as its likely cause (5). A large epidemic ensued, with major health and
- economic impacts (6), including over 8,400 reported cases (with ~20% among healthcare
- workers (HCWs)) across 32 countries up to mid-2003 (7–9). The epidemic was characterised
- by superspreading events, in which many infections occurred in a short timeframe in the
- same setting (e.g. hospitals or housing estates), and high fatality, with over 900 deaths
- 75 reported globally (10,11). Although no pharmaceutical countermeasures were available at the
- time, the epidemic was contained within a few months using traditional control measures,
- including risk communication, contact tracing, isolation and quarantine (12,13). These proved
- 78 effective, likely due to SARS's natural history, namely limited transmission from
- 79 asymptomatic and presymptomatic individuals (6).
- 80 In July 2003, the WHO declared the outbreak contained. A few sporadic cases, some due to
- 81 laboratory infections, emerged after 2003-2004. Nonetheless, SARS-CoV-1 still constitutes a
- 82 public health threat, currently on the WHO's list of priority pathogens for research and
- 83 development (15). Re-emergence of the virus from animals (bats being its main reservoir
- 84 (16)) or from laboratories are concerning prospects. Indeed, there is still no effective
- 85 treatment (17), and despite promising advances (18,19), there is no approved vaccine.
- 86 Many studies have investigated the epidemiology and transmission of SARS, leveraging
- 87 high-quality data on cases analysed with modern infectious disease epidemiology and
- 88 modelling approaches (20). Although multiple SARS systematic reviews have been published
- 89 (21–24) (Supplementary Material (SM) appendix E), they mainly focused on narrow aspects
- of SARS epidemiology (e.g. serial intervals, incubation periods or intervention effectiveness),
- and their static nature means there is no up-to-date resource providing a live picture of the
- 92 latest knowledge on SARS epidemiology and modelling. Our study aims to fill this gap: we
- 93 systematically reviewed published peer-reviewed SARS models and key epidemiological
- parameters. The extracted data are available in a flexible database that can be updated as new
- 95 information is produced.
- 96 Synthesising estimates of key epidemiological parameters is critical to support the response
- 97 to future SARS outbreaks. Robust epidemiological parameter estimates are also key inputs to
- mathematical models, which will likely be integral to future outbreak responses. Early
- analyses of the COVID-19 pandemic relied on assumptions that the natural history of SARS-
- 100 CoV-2 was similar to those of SARS-CoV-1 or MERS-CoV (25,26). Our database will

101 provide vital information to support early modelling efforts for future epidemics of SARS 102 and novel coronaviruses more broadly. 103 104 Methods 105 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 106 (PRISMA) guidelines. We registered our study protocol with PROSPERO (International 107 Prospective Register of Systematic Reviews, #CRD42023393345). 108 Search strategy and selection criteria 109 We searched PubMed and Web of Science for studies published from database inception up 110 to March 8, 2019. We repeated the search to include publications up to June 24, 2024. 111 Results were imported into Covidence (2024) (27) and de-duplicated. Titles and abstracts, 112 and then full texts were independently screened by two reviewers (selected from CM, TR, IR, 113 MR, NIE, JS, PD, HJTU, TN, DPD, AC, SB), and conflicts were resolved by consensus. 114 Non-peer-reviewed literature and non-English language studies were excluded. See Supplementary Material (SM) A.1 for further details on study selection, SM-Table A.1 for 115 116 full inclusion and exclusion criteria and SM-section D for the PRISMA checklists. 117 Data extraction 118 21% of full texts (n total=288) meeting the inclusion criteria were randomly selected and 119 double-extracted to validate the extraction process. A consensus on discordant results was 120 established, after which 20 reviewers (CM, TR, PD, KM, RJ, HJTU, TN, DPD, KP, BNCD, 121 AV, KOD, PC, RJS, SIL, JTH, RM, RKN, AC, SB) independently conducted single 122 extraction on the remaining full texts. Data on publication details, quality assessment (using a 123 customised questionnaire, see Data analysis section and SM-A.5), transmission model details, 124 basic and effective reproduction numbers, any epidemiological delays (e.g. incubation period 125 or symptom-onset-to-hospitalisation or -outcome delays), case fatality ratios (CFRs), attack 126 rates, growth rates, overdispersion, seroprevalence, and risk factors, were extracted using a 127 Microsoft Access database (version 2305). For risk factors, we extracted only whether-or-not 128 a factor was statistically significant, as reported in the articles, and if an analysis was adjusted 129 for other covariates. This is because differences in reference groups and stratification made it 130 unsuitable to compare other measures (e.g. odds ratios) across studies. We excluded 131 systematic reviews from our study but used them to cross-check that all eligible studies were 132 included (SM-section E). Full details of the data extraction process (SM-section A.2), 133 database structure (SM-tables B.6-B.7) and extracted data (SM-tables B.8-B.13) are provided 134 in SM. 135 136 Given there is a single documented SARS epidemic, we also analysed information on case 137 and death numbers reported by country from the final report of the Hong Kong SARS Expert 138 Committee (HKSEC) (10) to assess the global burden of the epidemic from a single source

139

140

without redundancy.

143

144

145

146

147

148

149

150

151

152

153

154

155

156157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Data analysis The risk of bias was assessed using a bespoke quality assessment (QA) questionnaire, with QA scores for each article calculated as the proportion of 'Yes' responses to applicable questions. A local polynomial regression was used to analyse temporal trends in QA scores (SM-Figure B.1). All manuscript figures show extracted parameters from "high QA" studies only, i.e. those with a QA score >50% (as in previous work (28)). Results from all studies are shown in SM Section B.5.1. For each parameter, we declare the total number of parameter extractions and studies and the number of high QA parameter extractions and studies. Analyses were conducted in R (version 4.2.2) (29); curated data on outbreaks, models, and epidemiological parameters were added to the *epireview* R package (30) (SM-section C). See SM section A.3.4 for how uncertainty is defined across all parameters. Meta-analyses of published estimates were conducted using the meta R package (31) for the mean incubation period and the mean symptom-onset-to-hospital-admission delay. Common and random effects models were used to generate pooled delay estimates with 95% confidence interval (CI) and  $I^2$  heterogeneity estimates (SM-A.3). We did not perform metaanalyses for other parameters due to insufficient estimates of central tendency paired with sample uncertainty. In addition to our review, we used data from the final HKSEC report (10), including the number of SARS cases, hospitalisations, deaths, recoveries, imported cases by country, and the onset dates for the first and last probable cases. We used this dataset to identify countries with local transmission and calculate CFRs for each country. We used mixed-effect logistic regression to obtain a pooled CFR estimate (Figure 2, SM-A.3.2). **Results** The search returned 28,356 potentially relevant articles. De-duplication retained 14,929 articles for title/abstract screening, 878 studies were retained for full-text screening, with 288 studies meeting the criteria for final inclusion (SM-Table A.1). As shown in Figure 1, the main reasons for study exclusion were "no reported parameters or models of interest" (n=220) and "no original estimates" (n=138). We report Cohen's kappa for the screening and full-text review (SM-Figure B.13). We extracted 519 parameters and 243 risk factors from 186 articles (SM-Tables B.3-4, B.8-13 and SM-Figure B.2) and 112 models from 108 articles (SM-Table B.5 and SM-Figure B.3). [FIGURE 1 here] Figure 2 illustrates the global burden of the 2003-2004 SARS epidemic, as estimated from the HKSEC final report (10). China reported the most cases (5327), followed by Hong Kong (1755), Taiwan (665), Canada (251), Singapore (238), and Vietnam (63). Local transmission was not documented elsewhere, though cases were reported in other countries.

180 [FIGURE 2 here] 181 We extracted 34 basic reproduction number ( $R_0$ ) estimates from 25 studies in total and 25 182 effective reproduction number (R<sub>t</sub>) estimates from 13 studies (SM-Tables B.4, B.8). R<sub>0</sub> 183 measures transmission without interventions and population immunity, whilst  $R_t$  captures 184 transmissibility, including as influenced by immunity, control measures, and behavioural 185 changes (32). Central R<sub>0</sub> estimates from 13 high-OA studies ranged between 1.1 and 88.3 186 (n=16). We omit two outlying estimates from our main analysis of 88.3 (33) and 12.985 (34) 187 due to their unique study contexts: one pertains to a nosocomial setting, and the other is from 188 a study investigating the impact of priors on Bayesian inference. The remaining 14 R<sub>0</sub> central 189 estimates from 11 studies ranged from 1.1 to 4.59, with uncertainty intervals spanning 0.25-5.31 (Figure 3A). R<sub>0</sub> estimates were similar across countries and the outbreak phase they 190 191 were estimated from (Figure 3A and SM-B.4, B.8). As expected, R<sub>t</sub> estimates tended to be 192 lower. Of the 17 R<sub>t</sub> estimates from 8 high-QA studies, 11 had a central value below or at the 193 threshold  $R_t=1$ , indicating a controlled epidemic, with the remaining six central  $R_t$  estimates 194 ranging from 2.4 to 4.8 (Figure 3B). All R<sub>t</sub> estimates from the start of the outbreak (n=5) were 195 above 1, while four mid-outbreak, two end-outbreak, and two control-measure period 196 estimates were below 1. 197 [FIGURE 3 here] 198 Five growth-rate estimates were extracted from three studies, 33 attack rates (AR) from 22 199 studies, and nine secondary attack rates from eight studies (SM-Tables B.4, B.8). 200 Growth rate central estimates ranged from 4.22%, corresponding to the midpoint of the range 201 of captured estimates in Zhang et al (35), to 16% per day (four estimates from two high-QA 202 studies, all estimated in the presence of control measures, Figure 4C), corresponding to a 203 doubling time between 4 and 16 days (SM-A.3). 204 AR estimates from the general population exclusively were generally low, with all but one 205 central estimate of high-QA studies ranging from 0 to 5.18%, corresponding to the mid-point 206 of the range of captured estimates of Rea et al (36) (n=11 from six studies) and one higher 207 estimate at 16.4% (Figure 4A). ARs in HCWs were substantially higher, with central 208 estimates ranging from 0.47 to 35.15% (n=7 from seven high-QA studies), as were ARs in 209 persons under investigation (close contacts or targeted studies), with central estimates ranging 210 from 0 to 40.5% (n=5 from four high-QA studies). 211 Secondary ARs showed a similar trend, with high estimates for HCWs (two central estimates 212 from two high-QA studies ranging from 18.7 - 19%) and persons under investigation (two 213 central estimates from two high-QA studies - 10.2 and 42.6%%, corresponding to the mid-214 point of the range of captured estimates of Shen et al (37)), and lower estimates in other 215 settings (three central estimates from two high-QA studies ranging from 6.2 to 14.9%, Figure 216 4B). 217 Overdispersion characterises heterogeneity in the number of secondary cases generated by 218 one individual, with lower overdispersion estimates indicating more heterogeneity or 219 superspreading. We extracted eight estimates of overdispersion from four studies (SM-B.8);

221

222

223

224

225

226

227228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

seven estimates for the three high-QA studies had central estimates ranging from  $7.52 * 10^{-7}$ to 0.285, with uncertainty extending as high as 1.48 (Figure 4D). We extracted 12 parameters detailing genetic mutation from six studies in total. Filtering for only high QA studies, we extracted two mutation rate (evolutionary rate) estimates from two studies, one of which also reported three substitution rate estimates (Figure 4E-F, SM-Table B.8). Central estimates ranged from 14 to  $30.15 \times 10^{-4}$  substitutions per site per year (s/s/y) for the evolutionary rate and from 15.90 to 50.15 x 10<sup>-4</sup> s/s/y for the substitution rate, where the central estimate corresponds to the mid-point of the range of captured estimates for each study. Uncertainty around those was not reported, but ranges of point estimates were provided, e.g. reflecting different fragments of the genome considered: one study reported central evolutionary rate estimates ranging from 4.2 to 23.4 x 10<sup>-4</sup> s/s/y, and three studies reported wide ranges of central substitution rates estimates, from 0 to 92.20 x 10<sup>-4</sup> s/s/y. [FIGURE 4 here] Seroprevalence estimates varied widely across studies, again depending on the population being investigated (SM-Table B12), with low seroprevalence in the general population and children and mixed groups outside hospital settings (8 seroprevalence estimates from 0 to 12.04% across five high-QA studies), moderate in HCWs (13 seroprevalence estimates from 0 to 88.9% across 11 high-QA studies), and high in persons under investigation (nine seroprevalence estimates from 0.19 to 100% across nine high-QA studies). 37 studies (31 high-QA) examined risk factors for SARS infection (SM-Table B.13, SM-Figure B.11-12). Most risk factors considered were found to be both non-significant and significant across different studies. Close or household contact with an infected individual and occupation were more frequently significantly (vs. non-significantly) associated with infection (SM-Figure B11 A). In contrast, age, sex and comorbidity were more likely to be non-significantly (vs. significantly) associated with infection. We extracted 116 CFR estimates from 77 articles (86 estimates from 56 high-QA studies) (SM-Table B.4 and B.11, SM-Figure B.2). Half of these (n=57 estimates from 42 studies) were computed using a naïve approach (i.e. dividing the number of deaths by the number of cases), which leads to biased estimates if some cases have unknown final status. This can often be the case in real-time analyses (38). Many studies did not explicitly specify the CFR estimation method (n=37 estimates from 24 studies). Of those which corrected for right censoring (n=22 estimates from 14 studies), CFR estimates ranged from 0.1 to 30.8%. Many studies were for the same countries (e.g., nine CFR estimates from four studies for China); hence, estimates were likely not independent. We, therefore, also estimated the CFR retrospectively from data in the HKSEC final report (10); the CFR varied by country, from 6.6% (95% confidence interval (CI) 5.9-7.2%) in mainland China to 27.1% (95% CI 23.7-30.6%) in Taiwan, with a pooled random effect estimate of 13.8% (95% CI 9.2-20.3%) and a pooled common effect estimate of 10.9% (95% CI 10.3-11.6%, Figure 2).

Many studies considered potential risk factors for severe disease (21 analyses from eight studies, SM-Figure B.11 B, ten analyses from three high-QA studies) or death (82 analyses from 36 studies, SM-Figure B.11 C, 62 from 27 high-QA studies). Age, comorbidities and sex were the most studied risk factors for both severe disease and death (SM Figure B.10). Most analyses found age and comorbidities to be significant risk factors for severe disease and death. Most studies that considered sex as a risk factor for severe disease found it to be significant; there was mixed evidence of sex being a risk factor for death (14 studies significant versus 12 studies not significant). Contacts with infected individuals, in or outside the household, were not found to be a significant risk factor for severe disease (n = 1 analysis from one study), but close contact was identified as a significant risk factor for death in three out of four analyses from three studies. Occupation and hospitalisation were often identified as significant risk factors for death (10 analyses from eight studies and three analyses from two studies, respectively).

We extracted three estimates of mean serial interval (SI) from two studies and seven estimates of the infectious period from seven studies (Figure 5A-B and SM-Table C.10). The three SI estimates (all from high-QA studies) were broadly consistent, albeit uncertainty was large, encompassing values from 6.77 to 18.55 days. Four central estimates of the infectious period across four high-QA studies ranged from 4.84 to 10 days (uncertainty range 5.8-14.3 days; note not all studies report uncertainty), with a fifth high-QA study yielding a much higher central estimate of 21.6 days (uncertainty 14.9 to 26.8 days).

We extracted 49 incubation period estimates from 39 studies, with 42 estimates from 32 high-QA studies, including 17 estimates with sufficient information for inclusion in a meta-analysis (Figure 5D and SM-Table B.10). The pooled mean incubation period estimate was 5.03 days (95% CI 4.87-5.18) using a common effects (CE) model, and 5.42 days (95% CI 4.75-6.09) using a random effects (RE) model. The high I² (93%) suggests substantial heterogeneity across studies. Meta-analyses restricted to specific study populations (general population, HCWs, mixed groups, and persons under investigation) highlighted small differences in the mean incubation period across populations, with high I² throughout, indicating high heterogeneities between studies within each subgroup. The mean incubation period was shortest in persons under investigation (RE estimate 4.93 days, 95% CI 4.01-5.85) and longest in the general population (6.33, 95% CI 4.86-7.80).

We extracted 38 estimates of the delay from onset of symptoms to hospitalisation from 33 studies, including 29 estimates from 25 high-QA studies eligible for inclusion in meta-analysis (Figure 5E and SM-Table B.10). The estimated mean onset-to-hospitalisation delay was 3.48 days (95% CI 3.34-3.62 days) using the CE model and 3.99 days (95% CI 3.29-4.69 days) using the RE model, with a high I<sup>2</sup> (95%) suggesting large heterogeneity across studies.

We extracted 21 estimates from 14 studies characterising the delay from hospitalisation to outcome (i.e. death or recovery, Figure 5C and SM-Table B.10). Central estimates ranged from 9.4 to 35.9 days for the mean time from hospitalisation to death (seven estimates from

305

306

307

308

309

310

311 312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

six high-QA studies) and from 19 to 29.7 days for the mean time from hospitalisation to recovery (six estimates from six high-QA studies). We also extracted 15 estimates from 14 studies of mean time in hospital, with central estimates ranging from 3 to 23 days across seven high-QA studies. We conducted our meta-analyses using only high-QA studies. None of the lower-QA studies provided sufficient information to be included in our meta-analyses; hence, these did not affect our results (SM-Figure B.6). [FIGURE 5 here] 112 SARS transmission models were extracted from 108 studies (SM-Figure B.3, SM-Tables B.5, B.9). Compartmental models were the most frequent model type (n=63 from 62 studies), followed by individual-based models (n=9 from nine studies), and branching processes (n=7 from seven studies). Most compartmental models (n=43 of 63) were deterministic. Approximately half of the extracted models had been calibrated using observed data. Models captured a wide range of interventions, including quarantine and contact tracing, as well as behaviour changes (SM-Figure B.3(F)). No model had publicly available code. **Discussion** In this systematic review, we compiled and analysed published epidemiological parameter estimates and mathematical models of SARS-CoV-1. SARS epidemiology has been well characterised overall, with 519 epidemiological parameters, 243 risk factors, and 112 mathematical models extracted in this review, covering multiple geographic regions affected by the 2003-2004 epidemic (Figure 2, SM-Figure B2). Synthesising this information in a central dynamic database, as we have done in the R package *epireview*, is critical to prepare for potential future outbreaks of SARS-CoV-1, a high-threat virus on the 2024 WHO list of priority pathogens (39). This central resource will also be useful for epidemic preparedness, to characterise the epidemiology of existing coronaviruses and anticipate the potential epidemiological profile of future ones. SARS was first detected in China and then affected multiple other countries. Unlike with SARS-CoV-2, however, international spread was limited, with local transmission only identified in a handful of countries. However, SARS transmissibility in the affected regions was high, with growth rate estimates translating into a doubling of cases every 4 to 16 days (Figure 4 growth rates converted to doubling times (SI A.3)), and R<sub>0</sub> estimates broadly ranging from 1.1-4.59 (Figure 3A). These R<sub>0</sub> estimates were obtained using varied statistical approaches and data types. They were reported in very heterogeneous formats, sometimes without any characterisation of uncertainty, making comparison and synthesis across studies challenging. These R<sub>0</sub> estimates are comparable to those for the SARS-CoV-2 wildtype (~2.5) (40) and generally slightly higher than for pandemic influenza (typically 1-2.5) (41–43). Detection of the SARS epidemic and the subsequent WHO global alert rapidly prompted interventions, including quarantine, isolation, strict hygiene measures in hospitals and social distancing (13,44). These eventually led to a decline in cases, consistent with a reduction of  $R_1$ : estimates at the start of the epidemic broadly align with the basic reproduction number, ranging from 2-4 (Figure

- 347 3B), whilst estimates later in the epidemic suggest interventions were effective, bringing  $R_t$
- 348 below 1.
- However, transmission was highly heterogeneous: overdispersion estimates suggest
- significant variations in the number of secondary infections generated by each case.
- Following the approach of Lloyd-Smith et al. (45), the range of central overdispersion
- estimates (between  $7.52 * 10^{-7}$  (post interventions) and 0.285 (pre interventions), Figure 4)
- suggests that approximately 91% of SARS-CoV-1 transmission can be attributed to the 20%
- most infectious individuals in the pre-intervention period but this increases to 99% in the
- post-intervention period (SI A.3.3). Hence, superspreading in SARS-CoV-1 is more
- prominent than for many other viruses (45), including SARS-CoV-2 (46). This characteristic
- 357 makes SARS particularly threatening, as higher levels of superspreading make epidemics
- 358 harder to control.
- 359 Attack rate, secondary attack rate, and seroprevalence estimates extracted in this review show
- that SARS-CoV-1 transmissibility highly depended on the sub-population considered, as
- observed during the COVID-19 pandemic (47). General population studies reported SARS-
- 362 CoV-1 attack rates and seroprevalence generally under 1% (Figure 4A and SM-Table B.12),
- 363 whilst estimates among HCWs were substantially higher, with central estimates ranging from
- 364 1.2% to 35.15%.
- 365 We extracted risk factors associated with infection (SM-Figure B.11). Unsurprisingly, close
- 366 contact with confirmed cases was frequently identified as a significant risk factor for
- 367 infection. Occupation, including HCWs, was also often reported as a significant risk factor
- for infection, in line with higher attack rates, secondary attack rates, and seroprevalence
- 369 estimated among HCWs.
- Published estimates of CFR suggest high severity, with >10% of cases fatal (SM-Table B.11
- and Figure 2). This is one order of magnitude higher than SARS-CoV-2 (CFR up to ~2% for
- 372 the most severe variants (48) (40)) and pandemic influenza (CFR up to ~1-3% for the 1918
- influenza pandemic (49)). Such high severity likely aided case identification and intervention
- targeting. However, combined with a relatively high transmissibility and high
- superspreading, it emphasises the threat posed by SARS-CoV-1 and potential future
- 376 coronaviruses that could share these characteristics.
- 377 Risk factors for hospitalisation and death were aligned with those previously identified for
- 378 respiratory viruses, including age and comorbidities. Sex demonstrated mixed results, with
- 379 studies equally identifying it as a significant and non-significant risk factor for SARS
- mortality. For COVID-19, the CFR is higher for men than for women (50). Being an HCW
- was frequently identified as being significantly associated with the risk of death. However,
- these results should be interpreted with caution as we did not extract the direction of the
- 383 association.
- 384 The natural history of SARS was less well-characterised. We identified only three estimates
- for the central estimate of the SI, all with considerable uncertainty (Figure 5A) and one
- estimate for the generation time. The few estimates for the infectious period suggested a
- duration of around a week. However, some uncertainty and an outlier again suggested a much
- longer infectious period of several weeks (Figure 5B). The mean incubation period was better

389 characterised, enabling a meta-analysis yielding a pooled RE model estimate of 5.42 days

- 390 (95% CI 4.75-6.09, Figure 5D), similar to estimates for SARS-CoV-2 (51). Subgroup
- analyses suggested variations in mean incubation periods across populations, although this
- may reflect differences in study designs and associated biases. Although not a focus of our
- 393 systematic review, very little evidence was found to suggest a role of asymptomatic
- 394 transmission for SARS. This suggests that most SARS-CoV-1 infectious individuals were
- 395 symptomatic, and their infectiousness started after symptoms, meaning that the latent period
- would be at least as long as the incubation period (52,53). Little or no asymptomatic
- transmission enables containment, as infectious individuals can be effectively isolated
- 398 following symptom onset. This contrasts with SARS-CoV-2, where asymptomatic
- transmission has been widely documented, limiting the effectiveness of control measures that
- rely on symptom-based case identification and isolation (54).
- Delay from symptom onset to hospitalisation is also an important marker of epidemic
- 402 management, with shorter delays characterising epidemics where cases are isolated more
- 403 promptly and which are more likely to be controlled. Our meta-analysis estimated a relatively
- short mean time from symptoms to hospitalisation of 3.99 days (95% CI 3.29-4.69) for the
- 405 RE model. However, there were substantial variations between studies, with no clear
- 406 indications of what factors may drive such heterogeneity (Figure 5E, SM-Figure B.8), except
- 407 that the delay reduced over time due to improved population awareness (55). Further studies
- 408 into drivers of delayed hospitalisation may help to control outbreaks of SARS-CoV-1 and
- other coronaviruses. Estimates of mean time in hospital were also highly variable between
- studies, even when considering only individuals who die or only individuals who recover
- 411 (Figure 5C). Similarly, further investigation of drivers of such heterogeneity would help
- adequately prepare increased healthcare capacity for future coronavirus outbreaks.
- 413 We identified only two high-QA studies reporting estimates of the substitution and
- 414 evolutionary rates for SARS-CoV-1, with widely ranging estimates for different genome
- 415 sections. The paucity of estimates is unsurprising given that the SARS epidemic happened
- 416 early in the 21<sup>st</sup> century when genetic sequencing was not yet commonly utilised. The higher
- end of those ranges, with evolutionary rates up to  $8*10^{-3}$  substitutions per site per year,
- 418 emphasises the potential for SARS and similar coronaviruses to evolve rapidly, possibly even
- faster than SARS-CoV-2 (56).
- 420 SARS modelling studies have been continuously published since 2003. Most modelling
- 421 studies contemporary with the 2003-2004 epidemic sought to infer epidemiological
- parameters and forecast epidemic trends based on data. In contrast, more recent modelling
- studies have predominantly been theoretical, using SARS as a case study to explore
- 424 methodological questions. While the QA scores of non-modelling studies remained broadly
- 425 constant, we noted a decline in QA scores of modelling studies over time (SM-Figure B1
- 426 (C)), possibly reflecting this shifting focus.
- None of the modelling studies provided associated model code, in line with recent estimates
- 428 that only 0.5% of medical studies to date provide public-access code (57). The absence of
- 429 code also likely reflects a less widespread practice of open-source code in 2003 compared to
- 430 2024, with journals and funders requiring open-source code only recently (58).

- 431 Our work has limitations. Firstly, we excluded non-peer-reviewed literature and studies not in
- English from our review. Restriction to peer-reviewed papers ensures our review adheres to
- high-quality standards. The language restriction means that we may have excluded relevant
- studies, particularly those in Chinese (SM-Table F.17). Secondly, to keep this review
- 435 manageable given the volume of peer-reviewed studies on SARS-CoV-2, we added a
- 436 "SARS-CoV-2" exclusion term to our search criteria. Therefore, studies comparing SARS-
- 437 CoV-1 and SARS-CoV-2 will have been omitted. Overall, given that the literature on SARS
- is based on a single well-documented epidemic, it is unlikely that these restrictions left out
- substantial pieces of knowledge not otherwise covered. Moreover, further relevant literature
- not covered here could, in the future, be added to our 'epireview' R package, where all
- information extracted in this review is already publicly available (30).
- When SARS-CoV-2 was first identified, initial assessments of potential epidemic impact and
- intervention options were informed by epidemiological and modelling analyses which, in the
- absence of characterisation of the new coronavirus, assumed that its natural history and
- epidemiology (e.g. degree of superspreading) would be similar to those of SARS-CoV-1 and
- MERS-CoV (25,26,59–61). Similar assumptions may need to be made in future outbreaks.
- Our systematic review and dynamic database will provide a critical resource to support the
- 448 timely development and robust parameterisation of mathematical models in future epidemics
- of SARS and novel coronaviruses.

# 451 **Declarations**

450

- 452 Funding All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global
- 453 Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global
- Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research
- Protection Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency
- 456 (UKHSA), Imperial College London, and London School of Hygiene & Tropical Medicine (grant code
- NIHR200908). AC was supported by the Academy of Medical Sciences Springboard scheme, funded by the
- 458 Academy of Medical Sciences, the Wellcome Trust, the UK Department for Business, Energy, and Industrial
- Strategy, the British Heart Foundation, and Diabetes UK (reference SBF005\1044) and acknowledges research
- funding from the Sergei Brin foundation. CM acknowledges the Schmidt Foundation for research funding (grant
- $461 \qquad \text{code } 6\text{--}22\text{--}63345). \ PD, \ TN, \ KP \ \text{acknowledge funding from Community Jameel. RJ \ acknowledges funding from Community Jameel.}$
- 462 CEPI. GC-D acknowledges funding from the Royal Society. KD acknowledges research funding from the Wellcome Trust (220885/Z/20/Z). RKN acknowledges research funding from the MRC Doctoral Training
- Wellcome Trust (220885/Z/20/Z). RKN acknowledges research funding from the MRC Doctoral Training Partnership (grant MR/N014103/1). KM acknowledges research funding from the Imperial College President's
- PhD Scholarship. The funders of the study had no role in study design, data collection, data analysis, data
- 466 interpretation, or writing of the report. For the purpose of open access, the author has applied a 'Creative
- Commons Attribution' (CC BY) licence to any Author Accepted Manuscript version arising from this
- 468 submission.

469

### Availability of data and materials

- 470 https://github.com/mrc-ide/epireview/tree/main/data
- Code availability https://github.com/mrc-ide/epireview; https://github.com/mrc-ide/priority-pathogens
- 472 **PROSPERO** CRD42023393345
- 473 (https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID&RecordID=393345)
- 474 Competing interests AC reports payment from Pfizer for teaching mathematical modelling of infectious

- diseases. PD reports payment from WHO for consulting on integrated modelling. RM has received payment
- 476 from WHO for work on MERS-CoV. HJTU reports payment from the Moderna Charitable Foundation (paid
- directly to institution for an unrelated project). All other authors declare no competing interests. The views
- 478 expressed are those of the authors and not necessarily those of the National Institute for Health and Care
- Research (NIHR), UK Health Security Agency, or the Department of Health and Social Care. NI-E is currently
- 480 employed by Wellcome. However, Wellcome had no role in the design and conduct of the study; collection,
- 481 management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and
- decision to submit the manuscript for publication.

### 483 Authors' contributions

- 484 SB, SvE, AC, and NI-E conceptualised this systematic review. CM, TR, IR, MR, NIE, JS, HJTU, AC, and SB
- searched the literature and screened the titles and abstracts. CM, TR, IR, MR, JS, PD, HJTU, TN, DPD, and AC
- 486 reviewed all full-text articles. CM, TR, PD, KM, RJ, HJTU, TN, DPD, KP, BNCD, AV, KOD, PC, RJS, SIL,
- 487 JTH, RM, RKN, AC, and SB extracted the data. CM, TR, AC and SB formally analysed, visualised, and
- 488 validated the data. CM, TR, TN, CNS, and SB were responsible for software infrastructure. AC acquired
- 489 funding. CM, TR, and AC were responsible for project administration. GC-D, HJTU, and RKN were
- 490 responsible for training individuals on accessing Covidence and designing the Access system. CM and AC
- supervised the systematic review. CM, TR, AC, and SB wrote the original manuscript draft. All authors were
- 492 responsible for the methodology and review and editing of the manuscript. All authors debated, discussed,
- edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to
- submit the manuscript for publication.

### References

495

- 497 1. Chowell G, Fenimore PW, Castillo-Garsow MA, Castillo-Chavez C. SARS outbreaks
- 498 in Ontario, Hong Kong and Singapore: the role of diagnosis and isolation as a control
- 499 mechanism. J Theor Biol. 2003 Sep;224(1):1–8.
- 500 2. Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, et al.
- 501 Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi
- Arabia: a descriptive genomic study. The Lancet. 2013 Dec;382(9909):1993–2002.
- 503 3. CMMID COVID-19 Working Group, Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M.
- 504 The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130
- countries and territories. BMC Med. 2021 Dec;19(1):40.
- 506 4. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic
- 507 Human Coronaviruses. In: Advances in Virus Research [Internet]. Elsevier; 2018 [cited 2024
- 508 Jun 17]. p. 163–88. Available from:
- 509 https://linkinghub.elsevier.com/retrieve/pii/S0065352718300010
- 510 5. CDC. CDC SARS Response Timeline [Internet]. 2013. Available from:
- 511 https://archive.cdc.gov/www\_cdc\_gov/about/history/sars/timeline.htm#:~:text=SARS%3A%
- 512 20Key%20Events,was%20stopped%20in%20July%202003.
- 513 6. Lee JW, McKibbin WJ. Learning from SARS: Preparing for the Next Disease
- 514 Outbreak: Workshop Summary. [Internet]. National Academies Press; 2004. Available from:

- 515 https://www.ncbi.nlm.nih.gov/books/NBK92473/
- 516 7. Xiao J, Fang M, Chen Q, He B. SARS, MERS and COVID-19 among healthcare
- workers: A narrative review. J Infect Public Health. 2020 Jun;13(6):843–8.
- 518 8. WHO. Severe Acute Respiratory Syndrome (SARS) [Internet]. Available from:
- 519 https://www.who.int/health-topics/severe-acute-respiratory-syndrome#tab=tab\_1
- 520 9. WHO. SARS outbreak contained worldwide [Internet]. WHO; 2003 Jul. Available
- from: https://www.who.int/news/item/05-07-2003-sars-outbreak-contained-worldwide
- 522 10. Hong Kong SARS Expert Committee. SARS in Hong Kong: from Experience to
- 523 Action, Chapter 4 Commentary on Key Issues [Internet]. 2003. Available from:
- 524 https://www.sars-expertcom.gov.hk/english/reports/files/e\_chp4.pdf
- 525 11. Sever Actute Respiratory Syndrome (SARS) Epidemiology Working Group.
- 526 Consensus document on the epidemiology of severe acute respiratory syndrome (SARS)
- 527 [Internet]. WHO; 2003. Report No.: WHO/CDS/CSR/GAR/2003.11. Available from:
- 528 https://iris.who.int/bitstream/handle/10665/70863/WHO\_CDS\_CSR\_GAR\_2003.11\_eng.pdf
- ?sequence=1&isAllowed=y
- 530 12. Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, Hedley AJ, et al.
- 531 Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public
- 532 Health Interventions. Science. 2003 Jun 20;300(5627):1961–6.
- 533 13. Bell DM, World Health Organization Working Group on Prevention of International
- and Community Transmission of SARS. Public Health Interventions and SARS Spread,
- 535 2003. Emerg Infect Dis. 2004 Nov;10(11):1900–6.
- 536 14. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious
- disease outbreak controllable. Proc Natl Acad Sci. 2004 Apr 20;101(16):6146–51.
- 538 15. WHO. Prioritizing diseases for research and development in emergency contexts
- [Internet]. Available from: https://www.who.int/activities/prioritizing-diseases-for-research-
- and-development-in-emergency-contexts
- 541 16. Wang LF, Shi Z, Zhang S, Field H, Daszak P, Eaton B. Review of Bats and SARS.
- 542 Emerg Infect Dis. 2006;12(12):1834–40.
- 543 17. Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects.
- 544 Low D, editor. PLoS Med. 2006 Sep 12;3(9):e343.
- 545 18. Cankat S, Demael MU, Swadling L. In search of a pan-coronavirus vaccine: next-
- 546 generation vaccine design and immune mechanisms. Cell Mol Immunol. 2023 Dec
- 547 26;21(2):103–18.
- 548 19. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, et al. A

- 549 SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy
- adults in a Phase I clinical trial. Vaccine. 2008 Nov;26(50):6338–43.
- 551 20. Olowokure B, Merianos A, Leitmeyer K, Mackenzie JS. Focus: SARS. Nat Rev
- 552 Microbiol. 2004 Feb;2(2):92–92.
- 553 21. Vink MA, Bootsma MCJ, Wallinga J. Serial Intervals of Respiratory Infectious
- 554 Diseases: A Systematic Review and Analysis. Am J Epidemiol. 2014 Nov 1;180(9):865–75.
- 555 22. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation
- periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009
- 557 May;9(5):291–300.
- 558 23. Teasdale E, Santer M, Geraghty AWA, Little P, Yardley L. Public perceptions of non-
- 559 pharmaceutical interventions for reducing transmission of respiratory infection: systematic
- review and synthesis of qualitative studies. BMC Public Health. 2014 Dec;14(1):589.
- 561 24. Kwok KO, Tang A, Wei VWI, Park WH, Yeoh EK, Riley S. Epidemic Models of
- 562 Contact Tracing: Systematic Review of Transmission Studies of Severe Acute Respiratory
- 563 Syndrome and Middle East Respiratory Syndrome. Comput Struct Biotechnol J.
- 564 2019;17:186–94.
- 565 25. Imai N, Dorigatti I, Cori A, Riley S, Ferguson N. Estimating the potential total
- 566 number of novel Coronavirus cases in Wuhan City, China [Internet]. Imperial College
- 567 London; 2020 Jan [cited 2024 Jul 23]. Available from:
- 568 http://spiral.imperial.ac.uk/handle/10044/1/77149
- 569 26. Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly C, Riley S, et al. Report 3:
- 570 Transmissibility of 2019-nCoV [Internet]. Imperial College London; 2020 Jan [cited 2024 Jul
- 571 23]. Available from: http://spiral.imperial.ac.uk/handle/10044/1/77148
- 572 27. Veritas Health Innovation. Covidence systematic review software [Internet].
- 573 Melbourne, Australia: Veritas Health Innovation; 2024. Available from: www.covidence.org
- Nash RK, Bhatia S, Morgenstern C, Doohan P, Jorgensen D, McCain K, et al. Ebola
- virus disease mathematical models and epidemiological parameters: a systematic review.
- 576 Lancet Infect Dis. 2024 Aug; \$1473309924003748.
- 577 29. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
- 578 Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from:
- 579 https://www.R-project.org/
- 580 30. Nash R, Morgenstern C, Santoni C, Bhatia S, Sheppard R, Hicks J, et al. epireview:
- Tools to update and summarise the latest pathogen data from the Pathogen Epidemiology
- Review Group (PERG) [Internet]. 2024. Available from: https://mrc-ide.github.io/epireview/

- 583 31. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a
- practical tutorial. Evid Based Ment Health. 2019;(22):153–60.
- 585 32. Fraser C. Estimating Individual and Household Reproduction Numbers in an
- 586 Emerging Epidemic. Galvani A, editor. PLoS ONE. 2007 Aug 22;2(8):e758.
- 587 33. Kwok KO, Leung GM, Lam WY, Riley S. Using models to identify routes of
- 588 nosocomial infection: a large hospital outbreak of SARS in Hong Kong. Proc R Soc B Biol
- 589 Sci. 2007 Mar 7;274(1610):611–8.
- 590 34. Moser CB, Gupta M, Archer BN, White LF. The Impact of Prior Information on
- 591 Estimates of Disease Transmissibility Using Bayesian Tools. Van Boven M, editor. PLOS
- 592 ONE. 2015 Mar 20;10(3):e0118762.
- 593 35. Zhang Z. The outbreak pattern of SARS cases in China as revealed by a mathematical
- 594 model. Ecol Model. 2007 Jun;204(3–4):420–6.
- 595 36. Rea E, Laflèche J, Stalker S, Guarda BK, Shapiro H, Johnson I, et al. Duration and
- 596 distance of exposure are important predictors of transmission among community contacts of
- 597 Ontario SARS cases. Epidemiol Infect. 2007 Aug;135(6):914–21.
- 598 37. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, et al. Superspreading SARS Events,
- 599 Beijing, 2003. Emerg Infect Dis. 2004 Feb;10(2):256–60.
- 600 38. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, et al. Methods for
- 601 Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease. Am J
- 602 Epidemiol. 2005 Sep 1;162(5):479–86.
- 603 39. WHO. Pathogens prioritization: a scientific framework for epidemic and pandemic
- 604 research preparedness [Internet]. 2024. Available from:
- 605 https://www.who.int/publications/m/item/pathogens-prioritization-a-scientific-framework-
- 606 for-epidemic-and-pandemic-research-preparedness
- 607 40. Perez-Guzman PN, Knock E, Imai N, Rawson T, Elmaci Y, Alcada J, et al.
- 608 Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. Nat
- 609 Commun. 2023 Jul 17;14(1):4279.
- 610 41. Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, Ramasco JJ, et al. Seasonal
- 611 transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo
- 612 likelihood analysis based on human mobility. BMC Med. 2009 Dec;7(1):45.
- 613 42. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza.
- 614 Nature. 2004 Dec;432(7019):904–6.
- 615 43. Boëlle P, Ansart S, Cori A, Valleron A. Transmission parameters of the A/H1N1
- 616 (2009) influenza virus pandemic: a review. Influenza Other Respir Viruses. 2011

- 617 Sep;5(5):306–16.
- 618 44. WHO. Disease Outbreak News, 2003 China [Internet]. 2003 Jul. Available from:
- 619 https://www.who.int/emergencies/disease-outbreak-news/item/2003\_07\_04-en
- 620 45. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of
- individual variation on disease emergence. Nature. 2005 Nov;438(7066):355–9.
- 622 46. Wegehaupt O, Endo A, Vassall A. Superspreading, overdispersion and their
- 623 implications in the SARS-CoV-2 (COVID-19) pandemic: a systematic review and meta-
- analysis of the literature. BMC Public Health. 2023 May 30;23(1):1003.
- 625 47. Ferland L, Carvalho C, Gomes Dias J, Lamb F, Adlhoch C, Suetens C, et al. Risk of
- 626 hospitalization and death for healthcare workers with COVID-19 in nine European countries,
- 627 January 2020–January 2021. J Hosp Infect. 2022 Jan;119:170–4.
- 628 48. Luo G, Zhang X, Zheng H, He D. Infection fatality ratio and case fatality ratio of
- 629 COVID-19. Int J Infect Dis. 2021 Dec;113:43-6.
- 630 49. Napoli C, Fabiani M, Rizzo C, Barral M, Oxford J, Cohen JM, et al. Assessment of
- human influenza pandemic scenarios in Europe. Eurosurveillance [Internet]. 2015 Feb 19
- 632 [cited 2024 Jul 20];20(7). Available from:
- 633 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2015.20.7.21038
- 634 50. Green MS, Nitzan D, Schwartz N, Niv Y, Peer V. Sex differences in the case-fatality
- 635 rates for COVID-19—A comparison of the age-related differences and consistency over
- 636 seven countries. Flacco ME, editor. PLOS ONE. 2021 Apr 29;16(4):e0250523.
- 637 51. Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY. Serial
- 638 interval and incubation period of COVID-19: a systematic review and meta-analysis. BMC
- 639 Infect Dis. 2021 Dec;21(1):257.
- 640 52. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al.
- 641 Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic. May
- RM, McLean AR, Pattison J, Weiss RA, editors. Philos Trans R Soc Lond B Biol Sci. 2004
- 643 Jul 29;359(1447):1091–105.
- 644 53. Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L, et al. Clinical progression and
- outbreak of coronavirus-associated SARS pneumonia: a
- 646 prospective study. The Lancet. 2003 May;361(9371):1767–72.
- 647 54. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et
- al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-
- 2 infections: A living systematic review and meta-analysis. Ford N, editor. PLOS Med. 2020
- 650 Sep 22;17(9):e1003346.

- 651 55. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al.
- 652 Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome
- 653 in Hong Kong. The Lancet. 2003 May;361(9371):1761–6.
- 654 56. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The
- evolution of SARS-CoV-2. Nat Rev Microbiol. 2023 Jun;21(6):361–79.
- 656 57. Hamilton DG, Hong K, Fraser H, Rowhani-Farid A, Fidler F, Page MJ. Prevalence
- and predictors of data and code sharing in the medical and health sciences: systematic review
- with meta-analysis of individual participant data. BMJ. 2023 Jul 11;e075767.
- 659 58. UKRI. UKRI open access policy [Internet]. 2023. Available from:
- 660 https://www.ukri.org/publications/ukri-open-access-policy/
- 59. Imai N, Dorigatti I, Cori A, Donnelly C, Riley S, Ferguson N. Report 2: Estimating
- the potential total number of novel Coronavirus cases in Wuhan City, China [Internet].
- 663 Imperial College London; 2020 Jan [cited 2024 Jul 23]. Available from:
- http://spiral.imperial.ac.uk/handle/10044/1/77150

672

673

- 665 60. Volz E, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunuba Perez Z, et al. Report
- 5: Phylogenetic analysis of SARS-CoV-2 [Internet]. Imperial College London; 2020 Feb
- [cited 2024 Jul 23]. Available from: http://spiral.imperial.ac.uk/handle/10044/1/77169
- 668 61. Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of
- 2019-novel coronavirus (nCoV) [Internet]. Imperial College London; 2020 Feb [cited 2024
- Jul 23]. Available from: http://spiral.imperial.ac.uk/handle/10044/1/77154




Figure 1: Study selection according to PRISMA guidelines and criteria described in SM-Table B.1. (Reasons for abstract exclusion not provided by Covidence).




Figure 2: Overview of the 2003-2004 SARS epidemic, based on final report of the Hong Kong SARS Expert Committee (10). Coloured countries and special administrative regions are those which reported confirmed SARS cases. Inset tables are shown for all locations with reported local SARS-CoV-1 transmission, indicating total cases, median age (except for China, for which median age was not reported), CFR, percentage of imported cases and dates of symptom onset of first and last case. In the bottom left corner, we report the mixed-effect logistic regression estimates of adjusted CFRs for locations with local transmission: red squares indicate location-specific estimates. Red diamonds represent overall common effect estimates - in which all aggregated data are assumed to come from a single data-generating process with one common CFR, and overall random effect estimates - that allow the CFR to vary by location and accordingly give different weights to each location in the overall estimate (SM-A.3.2). The "Events" column indicates the reported number of deaths. GLMM=generalised linear mixed-effects model (SM-A.3.2).




Figure 3: Overview of estimated SARS-CoV-1 (A) basic reproduction numbers  $(R_0)$  and (B) effective reproduction numbers  $(R_t)$ . Circles represent mean estimates, and triangles represent unspecified central estimates. Thin black solid lines represent uncertainty estimates, and solid shaded bars represent ranges of central estimates reported, e.g. when disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods. Colours represent when during the outbreak the study was conducted, as extracted by reviewers. The vertical dashed line indicates the threshold value of 1. Estimates are labelled with the country of study. CHN = China, HKG = Hong Kong, SGP = Singapore, CAN = Canada, TWN = Taiwan, VNM = Vietnam. Outlying estimates from Kwok (2007) (33) and Moser (2015) (34) are not displayed. Only parameters from studies with a QA score > 0.5 are plotted.




Figure 4: Overview of estimated SARS (A) attack rates, (B) secondary attack rates, (C) growth rates, (D) overdispersion, (E) evolutionary rates, (F) substitution rates. Circles represent mean estimates, and triangles represent unspecified central estimates. Thin solid lines represent uncertainty estimates, and solid shaded bars represent ranges of central estimates reported, e.g. when disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods (e.g. compartmental, branching process models, etc). Colour represents (A & B) the study population considered, (C & D) when during the outbreak the study was conducted, with "control measures" referring to a time in the outbreak when interventions were reported to be in place, (E & F) long (L)/short (S) gene segment. In E and F, s/s/y refers to nucleotide substitutions per site per year. Only parameters from studies with a QA score > 0.5 are plotted.




Figure 5: Overview of SARS epidemiological delays: estimates of (A) mean serial interval, (B) mean infectious period, (C) mean duration from hospital admission to final health outcome (i.e. death or recovery); and meta-analysis of epidemiological delays: estimates of (D) mean incubation period, (E) mean duration from symptom onset to hospital admission. In panels A, B, & C, circles represent mean estimates, squares represent median estimates, and triangles represent unspecified central estimates. Thin solid lines represent uncertainty estimates, and solid shaded bars represent the range of central estimates reported, e.g. when disaggregated by certain characteristics (e.g. age, sex, region, time) or using different estimation methods. In plot C, colour represents different final health outcomes. In D, blue squares indicate common effect and random effect estimates across different study populations, and blue diamonds represent: overall

common effect estimates - in which all aggregated data are assumed to come from a single data-generating process, and overall random effect estimates. In E, blue squares represent study-specific estimates, and blue diamonds represent overall common effect and random effect estimates. Only parameters from studies with a QA score > 0.5 are plotted.